A Brief History of Amgen Inc. (AMGN)

Amgen Inc., one of the world's leading biotechnology companies, was founded in 1980 by William K. Bowes, Jr., Raymond B. Waggoner, and several other pioneering scientists. The company, initially known as Applied Molecular Genetics Inc., quickly established itself as a key player in the burgeoning biotech industry.

In the early 1980s, Amgen focused on developing groundbreaking medical therapies through genetic engineering. Their efforts soon paid off, and the company began to experience significant milestones that would shape its future.

• 1983: Amgen went public and started trading on the NASDAQ stock exchange under the ticker symbol AMGN.
• 1989: The FDA approved Amgen's first blockbuster drug, Epogen (epoetin alfa), which is used to treat anemia associated with chronic kidney failure. Epogen's success solidified Amgen's reputation in the biotech industry.
• 1991: Neupogen (filgrastim) received FDA approval. Neupogen helps cancer patients undergoing chemotherapy by boosting white blood cell counts, thereby reducing infection risks.
• 2002: Amgen acquired Immunex Corporation, which added the rheumatoid arthritis drug Enbrel (etanercept) to its portfolio. This acquisition marked one of the most significant expansions in Amgen's history.
• 2004: Launch of Aranesp (darbepoetin alfa), an anemia drug similar to Epogen but with a longer half-life, further diversifying Amgen's product offerings.
• 2011: Amgen purchased BioVex Group, Inc., gaining access to an innovative oncolytic virus therapy for cancer.
• 2013: Acquisition of Onyx Pharmaceuticals, Inc., which specialized in developing treatments for cancer, expanded Amgen's footprint in oncology.
• 2015: The FDA approved Repatha (evolocumab), a cholesterol-lowering drug that became part of Amgen's cardiovascular portfolio.
• 2020: Amgen made a significant leap into the Asian market by acquiring a 20.5% stake in the Chinese biotech firm BeiGene, marking its commitment to global expansion.

Throughout its history, Amgen has focused on harnessing the power of scientific innovation to improve healthcare outcomes. With numerous patents and a robust pipeline of research and development projects, Amgen continues to be at the forefront of the biotechnology industry.

Who Owns Amgen Inc. (AMGN)

Amgen Inc. (AMGN) is a publicly traded biopharmaceutical company, and its ownership is distributed among various institutional investors, mutual funds, and individual shareholders. The company is listed on the NASDAQ stock exchange, and its shares are widely held by a diverse group of stakeholders.

Some of the most significant holders of Amgen Inc. stock include large institutional investors, which can possess substantial influence over company policies and decisions. Here's a breakdown of some notable shareholders:

• The Vanguard Group: Vanguard is one of the largest institutional investors in Amgen Inc., holding a significant percentage of the company's outstanding shares through various mutual funds and ETFs.
• BlackRock, Inc.: BlackRock, another global investment management corporation, owns a substantial portion of Amgen's shares, making it one of the top shareholders.
• State Street Corporation: This financial services and bank holding company also maintains a large stake in Amgen, contributing to its overall institutional ownership.
• Fidelity Management & Research (FMR) Co.: Fidelity, known for its mutual funds and investment management services, holds a significant number of shares in Amgen Inc., influencing its stockholder base.
• Capital Research and Management Company: This organization, which manages various investment funds, is among the major holders of Amgen stock.

Additionally, Amgen's executive team and board of directors may own shares in the company, aligning their interests with those of the shareholders. Individual investors who buy and sell Amgen's stock in the open market also contribute to the ownership structure.

The ownership landscape of Amgen Inc. reflects a mix of institutional and retail investors, each playing a role in the company's governance and performance in the stock market.

Amgen Inc. (AMGN) Mission Statement

Amgen Inc., a leader in biopharmaceuticals, is dedicated to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. The company's mission statement is pivotal in guiding its strategies and decisions.

Amgen's mission statement focuses on several critical areas:

• Innovative Science: Amgen aims to harness cutting-edge science and technology to develop therapies that significantly improve patients' lives.
• High-Quality Medications: The company strives to produce medications that meet the highest standards of quality and safety.
• Patient-Centric: A core part of Amgen's mission is to put patients at the forefront, ensuring that their needs and well-being drive their efforts and innovations.
• Collaborative Approach: Amgen values partnerships with healthcare professionals, scientists, and regulatory agencies to bring transformative treatments to market effectively.
• Responsibility and Integrity: The company is committed to ethical practices and responsibility in all its operations, ensuring trust and reliability within the healthcare ecosystem.

Overall, Amgen Inc.'s mission encapsulates its dedication to improving health outcomes through groundbreaking scientific advancements and a steadfast commitment to patient welfare.

How Amgen Inc. (AMGN) Works

Amgen Inc. (AMGN) is one of the world's leading biotechnology companies. Established in 1980 and headquartered in Thousand Oaks, California, the company is renowned for its innovative research, development, and commercialization of human therapeutics.

Amgen places a significant emphasis on research and development. The company spends a substantial portion of its revenue on R&D to discover and develop new medicines. Their R&D efforts are primarily focused on:

• Oncology
• Cardiovascular Disease
• Neuroscience
• Inflammation
• Bone Health
• Nephrology

Amgen is known for producing biologic medicines—therapies derived from living cells. These biologics offer targeted treatment options that are often more effective and have fewer side effects than traditional small-molecule drugs. Key biologics developed by Amgen include:

• Neulasta (pegfilgrastim)
• Enbrel (etanercept)
• Prolia (denosumab)
• Xgeva (denosumab)
• Kyprolis (carfilzomib)

Amgen operates state-of-the-art manufacturing facilities around the globe to ensure the consistent and reliable production of its therapies. These facilities adhere to rigorous quality control standards to meet regulatory requirements and ensure patient safety.

Amgen's commercial operations are expansive, covering major markets around the world. The company's strong global presence allows for the widespread availability of its therapies. Key regions include:

• North America
• Europe
• Asia-Pacific
• Latin America

Strategic partnerships play a crucial role in Amgen's business model. The company regularly collaborates with academic institutions, other biotech and pharmaceutical companies, and healthcare organizations to advance its R&D efforts and improve patient access to its therapies.

Amgen is dedicated to sustainability and corporate responsibility. The company actively works to minimize its environmental footprint, promote healthcare access, and engage in philanthropic activities. Some of their initiatives include:

• Reducing greenhouse gas emissions
• Improving energy efficiency
• Supporting community healthcare programs

Amgen places patients at the center of its operations. From early-stage development to post-market support, the company is committed to improving patient outcomes and enhancing the overall quality of life for those who use its therapies.

How Amgen Inc. (AMGN) Makes Money

Amgen Inc. (AMGN) is a leading biotechnology company that primarily generates revenue through the development, manufacturing, and marketing of human therapeutics. The company's business model focuses on several key areas to drive its financial performance.

• Product Sales: The majority of Amgen's revenue comes from the sale of its pharmaceutical products. These products are primarily focused on areas such as oncology, nephrology, cardiovascular disease, and inflammatory diseases. Key drugs like Enbrel, Neulasta, Prolia, and Repatha contribute significantly to the company's earnings.
• Research and Development (R&D): Amgen invests heavily in R&D to discover and develop new drugs. The company allocates a significant portion of its budget to advancing its pipeline of products, which, once approved, can generate substantial revenue. In addition, Amgen engages in partnerships and collaborations to enhance its R&D efforts.
• Licensing and Collaboration Agreements: Amgen enters into licensing and collaboration agreements with other biotechnology and pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of collaborated products, providing an additional stream of revenue.
• Acquisitions: Amgen also grows its portfolio through strategic acquisitions. By acquiring other companies or their products, Amgen can enhance its product line and enter new therapeutic areas, further diversifying its revenue sources.
• Biosimilars: As patents on biologic drugs expire, Amgen develops biosimilar versions of these drugs. Biosimilars are highly similar to already approved biologics, offering the same therapeutic benefits at a lower cost. This allows Amgen to capture a share of the market for these established treatments.
• Geographic Expansion: Amgen continues to expand its market presence globally. By entering new markets and increasing sales in existing ones, the company can grow its revenue base significantly. International sales contribute a substantial portion of Amgen's total revenue.

Overall, Amgen's diversified approach encompassing product sales, R&D, collaborations, acquisitions, biosimilars, and geographic expansion enables the company to maintain a strong financial position and continue to grow its revenue.